Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
PHASE-I AND PHARMACOLOGICAL STUDY OF INTRAARTERIAL HEPATIC ADMINISTRATION OF PIRARUBICIN IN PATIENTS WITH ADVANCED HEPATIC METASTASES
Autore:
MUNCK JN; ROUGIER P; CHABOT GG; RAMIREZ LH; BOGNEL C; LUMBROSO J; HERAIT P; ELIAS D; LASSER P; GOUYETTE A;
Indirizzi:
INST GUSTAVE ROUSSY,DEPT MED,PHARMACOL CLIN LAB F-94805 VILLEJUIF FRANCE INST GUSTAVE ROUSSY,INSERM,U140 F-94805 VILLEJUIF FRANCE INST GUSTAVE ROUSSY,CNRS,URA 147 F-94805 VILLEJUIF FRANCE INST GUSTAVE ROUSSY,DEPT MED IMAGING F-94805 VILLEJUIF FRANCE INST GUSTAVE ROUSSY,DEPT CHIRURG F-94805 VILLEJUIF FRANCE INST GUSTAVE ROUSSY,DEPT ANAT PATHOL F-94805 VILLEJUIF FRANCE ROGER BELLON LAB F-92200 NEUILLY SUR SEINE FRANCE
Titolo Testata:
European journal of cancer
fascicolo: 3, volume: 30A, anno: 1994,
pagine: 289 - 294
SICI:
0959-8049(1994)30A:3<289:PAPSOI>2.0.ZU;2-T
Fonte:
ISI
Lingua:
ENG
Soggetto:
ARTERIAL INFUSION; ADRIAMYCIN; CHEMOTHERAPY; LIVER;
Keywords:
DOXORUBICIN; PIRARUBICIN; INTRAARTERIAL HEPATIC CHEMOTHERAPY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
20
Recensione:
Indirizzi per estratti:
Citazione:
J.N. Munck et al., "PHASE-I AND PHARMACOLOGICAL STUDY OF INTRAARTERIAL HEPATIC ADMINISTRATION OF PIRARUBICIN IN PATIENTS WITH ADVANCED HEPATIC METASTASES", European journal of cancer, 30A(3), 1994, pp. 289-294

Abstract

Intra-arterial hepatic (i.a.h.) administration of the doxorubicin analogue pirarubicin was evaluated in a phase I trial, based on preclinical studies that showed an advantage of pirarubicin over doxorubicin after locoregional hepatic administration. Pirarubicin was given to 9 patients with metastatic liver disease with intrapatient dose escalation. Of the 58 cycles evaluable for tolerance, no hepatobiliary or vascular toxicity was observed. The dose-limiting toxicity was granulocytopenia: the maximum administered doses ranged from 50 to 120 mg/m(2), suggesting variable rates of pirarubicin hepatic extraction between patients. Pharmacokinetic data obtained in 7 patients, in which a direct comparison of intravenous (i.v.) and i.a.h. administration was possible,indicated a median i.v./i.a.h. ratio of 7.4 for the maximal plasma concentration, and a median ratio of 4 for the area under the plasma concentrations versus time curves, suggesting a high pirarubicin hepatic extraction. An unexpectedly high response rate was observed: two complete (colorectal carcinoma) and two partial responses. These data demonstrate that i.a.h. pirarubicin not only produced high locoregional concentrations and reduced systemic exposure, but can also achieve responses in metastatic liver disease of colorectal origin.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/12/20 alle ore 14:14:29